hydrazine has been researched along with Chronic Disease in 92 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (7.61) | 18.7374 |
| 1990's | 3 (3.26) | 18.2507 |
| 2000's | 15 (16.30) | 29.6817 |
| 2010's | 61 (66.30) | 24.3611 |
| 2020's | 6 (6.52) | 2.80 |
| Authors | Studies |
|---|---|
| Angchaisuksiri, P; Elghandour, A; Frueh, JA; Goldbrunner, M; Ingles, S; Jang, JH; Mattar, M; Ozcan, M; Rahman, M; Tarkun, P; Wei, X; Wong, RSM; Yang, R; Yassin, MA; Yavaşoğlu, İ; Yoon, SS | 1 |
| Bolster, L; Goodyear, MD; Patterson, JM; Podstawka, J; Rydz, N; Sun, HL; Wall, E | 1 |
| Borchiellini, A; Carli, G; d'Amore, ESG; Lucchini, E; Merli, M; Motta, G; Passamonti, F; Quaresimini, G; Rambaldi, A; Rodeghiero, F; Romano, A; Ruggeri, M; Santi, RM; Valeri, F; Visco, C; Volpetti, S | 1 |
| Ambrosiani, L; Feltri, M; Gardellini, A; Guidotti, F; Saccà, V; Turrini, M; Zancanella, M | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Aguilar-Calderón, P; Gómez-Almaguer, D; Jaime-Pérez, JC; Jiménez-Castillo, RA; Ramos-Dávila, EM; Salazar-Cavazos, L | 1 |
| Chen, M; Fang, JP; Li, XY; Lin, SF; Xu, LH; Zhou, CX | 1 |
| Grainger, JD; Thind, S | 1 |
| Ehrlich, LA; Farrell, AT; Ko, CW; Kwitkowski, VE; Nie, L; Pazdur, R; Reaman, G | 1 |
| Aguilar, C; Alvarez-Román, MT; Arrieta-Cerdán, E; Bárez, A; Bernat, S; de Cabo, E; Fernández-Fuertes, F; Fernández-Rodríguez, A; García-Frade, LJ; González-López, TJ; González-Porras, JR; Hernández-Rivas, JA; Martínez-Robles, V; Olivera, P; Pascual, C; Peñarrubia, MJ; Pérez-Rus, G; Sánchez-González, B | 1 |
| Agnelli Giacchello, J; Boccadoro, M; Borchiellini, A; Valeri, F | 1 |
| Bhor, M; Briggs, A; Dolph, M; Forsythe, A; Hearnden, J; Kwon, CS; Roy, A; Tremblay, G | 1 |
| Baydildina, DD; Kalinina, II; Maschan, AA; Novichkova, GA; Petrova, UN; Pshonkin, AV; Suntsova, EV | 1 |
| Atkinson, K | 1 |
| Hu, X; Jia, R; Li, S; Mai, H; Peng, Q; Wang, Y; Wu, S; Xie, Y | 1 |
| Caputo, I; D'Amore, F; Da Dalt, G; Friziero, A; Lombardi, AM; Vianello, F | 1 |
| Bakshi, KK; Brainsky, A; Tarantino, MD | 1 |
| D'Arena, G; Guariglia, R; Lerose, R; Mansueto, G; Martorelli, MC; Musto, P; Pietrantuono, G; Villani, O | 1 |
| Arnold, DM; Ghadaki, B; Kelton, JG; Nazi, I | 1 |
| Afdhal, NH; Giannini, EG | 1 |
| Brainsky, A; Fogarty, P; Mayer, B; Tarantino, MD; Vasey, SY | 1 |
| Aguilar, C | 1 |
| Brereton, N; Deuson, R; Hirst, A; Kutikova, L; Lee, D; Thornton, P | 1 |
| Hattori, T; Ikeda, Y; Ishii, K; Kanakura, Y; Katsura, K; Katsutani, S; Kimura, A; Kosugi, H; Miyakawa, Y; Ninomiya, H; Okamoto, S; Okoshi, Y; Tomiyama, Y | 1 |
| Farrell, C; Hayes, SC; Wire, M; Zhang, J | 1 |
| Brainsky, A; Fogarty, PF; Shah, P; Tarantino, MD | 1 |
| Bussel, JB; Hsieh, L; Leven, E; Nugent, D; Ramaswamy, K; Thompson, MV | 1 |
| Boulad, N; Bussel, JB; Edison, MN; Josefsson, EC; Kaplan, D; Karpoff, M; Kile, BT; Mitchell, WB; Pinheiro, MP; Psaila, B; White, MJ | 1 |
| Nakao, S | 1 |
| Aguilar, C; Alonso, A; Alonso, R; Álvarez-Román, MT; Andrade, MM; Arratibel, MC; Beneit, P; Bernat, S; Calbacho, M; Caparrós, I; Casaus, A; Coria, E; Cortés, M; Cortti, MJ; de Cabo, E; de Cos, C; Fernández-Canal, C; Fernández-Fuertes, F; Fernández-Miñano, C; Fernández-Rodríguez, A; Fisac, R; Fuertes-Palacio, MA; Galán, P; Garcia-Frade, J; Gómez-Núñez, M; González-López, TJ; González-Porras, JR; González-Silva, M; Gutierrez-Jomarrón, I; Hernández-Rivas, JA; Jarque, I; Jiménez, R; Luaña, A; Martín-Salces, M; Martínez-Robles, V; Mingot-Castellano, ME; Olivera, PE; Pascual, C; Paz Martínez-Badas, M; Peñarrubia, MJ; Perera, M; Pérez-Crespo, S; Pérez-Rus, G; Sainz, A; Sánchez-González, B; Solán, L; Valcarce, I; Vázquez-Paganini, JA | 1 |
| Dawson, KL; Grotzinger, KM; Kuter, DJ; Macahilig, C; Poston, SA; Wang, PF; Ward, M | 1 |
| Bailey, CK; Bakshi, KK; Brynes, RK; Burgess, P; Orazi, A; Thein, MM; Theodore, D | 1 |
| Bailey, CK; Bakshi, KK; Bussel, JB; Chagin, KD; Chan, GW; Chotsampancharoen, T; Donyush, E; Drelichman, G; Grainger, JD; Holzhauer, S; Iyengar, M; Komvilaisak, P; Lebedev, V; Lemons, R; Locatelli, F; Marcello, LM; Pongtanakul, B; Pospisilova, D; Ramenghi, U; Sirachainan, N; Sosothikul, D; Theodore, D | 1 |
| Locatelli, F; Merli, P; Palumbo, G; Strocchio, L; Vinti, L | 1 |
| Bai, LY; Chang, YF; Chen, CG; Chen, TY; Chiou, TJ; Hsueh, EJ; Kao, CW; Lan, YJ; Lin, HY; Lin, SF; Sung, YC; Wang, MC | 1 |
| de Knegt, RJ; Maan, R; Veldt, BJ | 1 |
| Aguilar, C; Alvarez-Román, MT; Andrade, MM; Bárez, A; Bernat, S; Cortés, M; de Cabo, E; Fernández-Fuentes, F; Fernández-Miñano, C; Fernández-Rodríguez, A; Fisac, R; Fuertes-Palacio, MA; García-Frade, LJ; Gómez-Nuñez, M; González-López, TJ; González-Porras, JR; Hernández-Rivas, JA; Jarque, I; Martínez-Robles, V; Olivera, P; Pascual, C; Peñarrubia, MJ; Pérez-Crespo, S; Pérez-Rus, G; Sánchez-González, B | 1 |
| Burness, CB; Garnock-Jones, KP; Keating, GM | 1 |
| Ashal, GE; Elfil, M; Elgebaly, AS; Menshawy, A | 1 |
| Chaimani, A; Desborough, M; Doree, C; Estcourt, LJ; Hadjinicolaou, AV; Hopewell, S; Stanworth, SJ; Trivella, M; Vyas, P | 1 |
| Kurokawa, T; Murata, S; Ohkohchi, N | 1 |
| Bakshi, KK; Brynes, RK; Burgess, P; Orazi, A; Thein, MM; Theodore, D; Wong, RS | 1 |
| Ostojic, SK; Rogulj, IM; Vibor, M | 1 |
| Bogdán, D; Borbély, É; Botz, B; Csepregi, JZ; Helyes, Z; Horváth, Á; Juhász, T; Keeble, J; Kemény, Á; Mátyus, P; Menghis, A; Mócsai, A; Pintér, E; Tékus, V; Zákány, R | 1 |
| Tomiyama, Y | 1 |
| Arnason, JE; Bussel, JB; Levy, B | 1 |
| Burzynski, J | 1 |
| Francesco, R | 1 |
| Pabinger, I; Panzer, S | 1 |
| Arning, M; Bussel, JB; Cheng, G; Jenkins, JM; Kovaleva, L; Mayer, B; Provan, D; Psaila, B; Roychowdhury, D; Salama, A; Shamsi, T; Stone, N | 1 |
| Nurden, AT; Nurden, P; Viallard, JF | 1 |
| Panzer, S | 2 |
| Lam, MS | 1 |
| Dmytrijuk, A; Pazdur, R; Rieves, D; Robie-Suh, K | 1 |
| Molineux, G; Newland, A | 1 |
| Olsson, B; Wadenvik, H | 1 |
| Chouhan, JD; Herrington, JD | 1 |
| Cook, L; Cooper, N | 1 |
| Aivado, M; Arning, M; Bussel, JB; Cheng, G; Marcher, C; Mayer, B; Saleh, MN; Stone, NL; Vasey, S | 1 |
| Nurden, AT | 1 |
| Meyer, O; Salama, A | 1 |
| Brainsky, A; Grotzinger, KM; Signorovitch, J | 1 |
| Boyers, D; Crowther, M; Fraser, C; Jenkinson, D; Jia, X; Mowatt, G | 1 |
| Fukunaga, S; Hori, A; Ono, S; Tanimoto, T; Yagasaki, F | 1 |
| Duan, X; Ni, X; Xu, J; Zeng, Y | 1 |
| Garnock-Jones, KP | 2 |
| Bolton-Maggs, PH; Collins, R; Emohare, O; Kaczmarski, R; Myers, B; Scully, M | 1 |
| Hattori, T; Ikeda, Y; Kanakura, Y; Katsura, K; Katsutani, S; Kimura, A; Kosugi, H; Miyakawa, Y; Ninomiya, H; Nomura, S; Okamoto, S; Okoshi, Y; Ozaki, K; Tomiyama, Y | 1 |
| Fujiyama, S; Hattori, T; Katsura, K; Kawaguchi, T; Komori, A; Nakamuta, M; Oketani, M; Sakisaka, S; Sasaki, Y; Sata, M; Seike, M; Tanaka, M; Watanabe, H | 1 |
| Biancotto, A; Calvo, KR; Desmond, R; Dumitriu, B; Dunbar, CE; Feng, X; Lozier, J; Olnes, MJ; Parikh, AR; Scheinberg, P; Soto, S; Tang, Y; Wu, CO; Young, NS | 1 |
| Joshi, A; Noronha, V; Philip, SD; Prabhash, K | 1 |
| Afdhal, NH; Andriulli, A; Brainsky, A; Campbell, F; Chen, PJ; Giannini, EG; Han, KH; Hyde, D; Jeffers, L; Lee, JW; McHutchison, J; Mohsin, A; Tayyab, G; Theodore, D | 1 |
| Aiba, K; Furukawa, K; Futagawa, Y; Ito, R; Misawa, T; Uwagawa, T; Yahagi, Y; Yanaga, K | 1 |
| Arning, M; Bailey, CK; Brainsky, A; Bussel, JB; Cheng, G; Meyer, O; Saleh, MN | 1 |
| Arning, M; Bussel, JB; Mayer, B; Saleh, MN; Stone, NL; Vasey, SY | 1 |
| Chrousos, GP; Goldstein, DS; Hoff, T; Koch, CA; Pacak, K; Palkovits, M; Tjurmina, O | 1 |
| Buikema, H; de Zeeuw, D; Gschwend, S; Henning, RH; Pinto, YM; van Gilst, WH | 1 |
| DUNLOP, E | 1 |
| Gómez, FM; Prieto, M; Teresa Giralt, M | 1 |
| Arning, M; Bussel, JB; Cheng, G; Hassani, H; Jenkins, JM; Kloczko, J; Kovaleva, L; Mayer, B; Meddeb, B; Provan, D; Psaila, B; Saleh, MN; Stone, NL | 1 |
| Newland, A | 1 |
| Hatano, M; Hibiya, K; Ichikawa, M; Nagasawa, M; Ozawa, Y; Saito, S; Tamura, Y; Tomobe, K; Yumikura, S | 1 |
| Fedotov, DD; Filippov, VL; Filippova, OI; Kiselev, DB | 1 |
| Brambilla, F; Guastalla, A; Maffei, C; Nobile, P; Ponzano, M; Rovere, C; Scarone, S | 1 |
| Abercrombie, ED; Nisenbaum, LK | 1 |
| Mayhan, WG | 1 |
| Bogdanov, NA | 1 |
| Kwarecki, K; Rozyński, J; Sarol, Z; Swiecicki, W | 1 |
| Cavallero, P; Fazio, M; Minetto, E; Sartoris, S | 1 |
| Epperlein, H; Göggel, KH | 1 |
29 review(s) available for hydrazine and Chronic Disease
| Article | Year |
|---|---|
Autoimmune pancytopenia following chronic immune thrombocytopenia: Case report and literature review.
Topics: Aged; Benzoates; Bone Marrow; Chronic Disease; Cyclosporine; Humans; Hydrazines; Immunologic Factors; Immunosuppressive Agents; Male; Pancytopenia; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Rituximab | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Chronic Disease; Female; Humans; Hydrazines; Infant; Infant, Newborn; Male; Practice Guidelines as Topic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2017 |
Thrombopoietin Receptor Agonists: Eltrombopag and Romiplostim for the Treatment of Chronic Immune Thrombocytopenia Purpura.
Topics: Adult; Benzoates; Child; Chronic Disease; Humans; Hydrazines; Patient Education as Topic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2019 |
Eltrombopag in patients with chronic liver disease.
Topics: Animals; Benzoates; Chronic Disease; Hematologic Agents; Humans; Hydrazines; Liver Diseases; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Thrombopoiesis; Treatment Outcome | 2013 |
Potential usefulness of thrombopoietin receptor agonists in haemophiliacs with thrombocytopaenia due to chronic liver disease.
Topics: Benzoates; Blood Platelets; Chronic Disease; Drug Dosage Calculations; Hemophilia A; Hemorrhage; Hepatitis C, Chronic; Humans; Hydrazines; Liver Cirrhosis; Platelet Count; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Risk Factors; Thrombocytopenia; Thrombopoietin | 2013 |
[Recent progress in the management of aplastic anemia].
Topics: Acute Disease; Anemia, Aplastic; Antilymphocyte Serum; Benzoates; Chronic Disease; Cyclosporine; Disease Progression; Hematopoiesis; Humans; Hydrazines; Immunosuppressive Agents; Pyrazoles | 2014 |
Eltrombopag for treatment of thrombocytopenia-associated disorders.
Topics: Anemia, Aplastic; Animals; Benzoates; Chronic Disease; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Hepatitis, Chronic; Humans; Hydrazines; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Thrombopoiesis | 2015 |
Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.
Topics: Benzoates; Chronic Disease; Disease Management; Hepatitis C, Chronic; Humans; Hydrazines; Liver Diseases; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thiazoles; Thiophenes; Thrombocytopenia; Thrombopoietin | 2015 |
Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.
Topics: Adolescent; Benzoates; Blood Platelets; Child; Child, Preschool; Chronic Disease; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Hemorrhage; Humans; Hydrazines; Infant; Multicenter Studies as Topic; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin | 2016 |
Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia: Meta-Analysis of Randomized Controlled Trials.
Topics: Adolescent; Adult; Benzoates; Child; Child, Preschool; Chronic Disease; Female; Humans; Hydrazines; Infant; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic | 2017 |
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
Topics: Benzoates; Bone Marrow Diseases; Chronic Disease; Deamino Arginine Vasopressin; Hemorrhage; Hemostatics; Humans; Hydrazines; Platelet Transfusion; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoietin; Tranexamic Acid | 2016 |
Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview.
Topics: Adult; Benzoates; Blood Platelets; Chronic Disease; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Splenectomy; Thrombopoietin | 2017 |
[Autoimmune (idiopathic) thrombocytopenic purpura].
Topics: Acute Disease; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Benzoates; Biomarkers; Blood Platelets; Chronic Disease; Female; Humans; Hydrazines; Immunoglobulin G; Immunosuppressive Agents; Male; Platelet Glycoprotein GPIb-IX Complex; Platelet Glycoprotein GPIIb-IIIa Complex; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Rituximab; Splenectomy | 2008 |
The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia.
Topics: Benzoates; Blood Platelets; Carrier Proteins; Chronic Disease; Clinical Trials as Topic; Hemorrhage; Hepatitis C; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin; Treatment Outcome | 2008 |
New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
Topics: Benzoates; Carrier Proteins; Chronic Disease; Drug Approval; Hemorrhage; Humans; Hydrazines; Megakaryocytes; Methacrylates; Patient Selection; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Safety; Thiazoles; Thiophenes; Thrombopoiesis; Thrombopoietin; Treatment Outcome; United States; United States Food and Drug Administration | 2009 |
Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia.
Topics: Benzoates; Chronic Disease; Dose-Response Relationship, Drug; Hepacivirus; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia | 2009 |
Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.
Topics: Adult; Animals; Benzoates; Chronic Disease; Controlled Clinical Trials as Topic; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Thrombopoietin | 2010 |
Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside.
Topics: Adult; Aged; Aged, 80 and over; Animals; Benzoates; Chronic Disease; Clinical Trials as Topic; Drug Discovery; History, 18th Century; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Hydrazines; Mice; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Thrombopoietin; Young Adult | 2010 |
Moving towards a new era in the management of chronic immune thrombocytopenia.
Topics: Benzoates; Chronic Disease; Hemorrhage; Hydrazines; Medication Therapy Management; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2010 |
Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzoates; Chronic Disease; Clinical Trials, Phase III as Topic; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thrombopoiesis; Thrombopoietin | 2010 |
Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.
Topics: Animals; Benzoates; Blood Platelets; Chronic Disease; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic | 2010 |
Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP).
Topics: Benzoates; Chronic Disease; Cost-Benefit Analysis; Humans; Hydrazines; Meta-Analysis as Topic; Models, Economic; Platelet Count; Pyrazoles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Splenectomy; Thrombocythemia, Essential; Thrombopoietin | 2011 |
TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.
Topics: Benzoates; Chronic Disease; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2011 |
Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
Topics: Adult; Animals; Benzoates; Chronic Disease; Drug Interactions; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Time Factors | 2011 |
Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
Topics: Benzoates; Chronic Disease; Clinical Trials as Topic; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin | 2011 |
New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; B-Lymphocytes; Benzoates; Carrier Proteins; Chronic Disease; Clinical Trials as Topic; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Splenectomy; Thrombopoietin | 2008 |
Emerging strategies to treat chronic immune thrombocytopenic purpura.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzoates; Chronic Disease; Humans; Hydrazines; Immunoglobulins, Intravenous; Intercellular Signaling Peptides and Proteins; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Rituximab; Splenectomy; Thrombopoiesis; Thrombopoietin | 2008 |
[Clinical aspects and diagnosis of chronic poisonings with the components of rocket fuels].
Topics: Aerospace Medicine; Ammonia; Chronic Disease; Fluoride Poisoning; Fossil Fuels; Humans; Hydrazines; Military Medicine; Monomethylhydrazine; Neurologic Manifestations; Nitrates; Nitrogen Oxides; Poisoning; Space Flight | 1974 |
22 trial(s) available for hydrazine and Chronic Disease
| Article | Year |
|---|---|
Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Chronic Disease; Female; Humans; Hydrazines; Lymphoproliferative Disorders; Male; Middle Aged; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2019 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Treatment outcomes and chronicity predictors for primary immune thrombocytopenia: 10-year data from an academic center.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Benzoates; Child; Child, Preschool; Chronic Disease; Dexamethasone; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Infant; Infant, Newborn; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retrospective Studies; Rituximab; Splenectomy | 2020 |
Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.
Topics: Aged; Benzoates; Chronic Disease; Follow-Up Studies; Humans; Hydrazines; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2017 |
Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Hemorrhage; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin | 2013 |
Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study.
Topics: Administration, Oral; Adult; Aged; Asian People; Benzoates; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Time Factors; Treatment Outcome | 2013 |
Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.
Topics: Adult; Benzoates; Bone Marrow; Bone Marrow Examination; Chronic Disease; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Primary Myelofibrosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Reticulin | 2015 |
Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Chronic Disease; Double-Blind Method; Female; Humans; Hydrazines; Infant; Male; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome | 2015 |
Stable Liver Function during Long-Term Administration of Eltrombopag, a Thrombopoietin Receptor Agonist, in Patients with Chronic Liver Disease.
Topics: Aged; Benzoates; Chronic Disease; Humans; Hydrazines; Liver; Liver Diseases; Liver Function Tests; Long-Term Care; Male; Middle Aged; Platelet Count; Pyrazoles; Receptors, Thrombopoietin | 2016 |
A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Biopsy; Bone Marrow; Chronic Disease; Collagen; Female; Humans; Hydrazines; Male; Middle Aged; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Reticulin | 2017 |
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chronic Disease; Female; Hemorrhage; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Young Adult | 2009 |
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
Topics: Adult; Benzoates; Chronic Disease; Double-Blind Method; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Splenectomy | 2011 |
Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia.
Topics: Benzoates; Chronic Disease; Dose-Response Relationship, Drug; Fatigue; Female; Hemorrhage; Humans; Hydrazines; Male; Prospective Studies; Pyrazoles; Receptors, Thrombopoietin; Reproducibility of Results; Sickness Impact Profile; Thrombocytopenia; Time | 2011 |
Eltrombopag named patient programme for patients with chronic immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Child; Child, Preschool; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2012 |
A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.
Topics: Administration, Oral; Adult; Aged; Asian People; Benzoates; Blood Platelets; Chronic Disease; Double-Blind Method; Female; Hematologic Agents; Hemorrhage; Humans; Hydrazines; Japan; Male; Middle Aged; Placebos; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Time Factors; Treatment Outcome | 2012 |
Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Hydrazines; Liver Diseases; Male; Middle Aged; Platelet Count; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2012 |
Eltrombopag and improved hematopoiesis in refractory aplastic anemia.
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Benzoates; Bone Marrow Cells; Chronic Disease; Drug Resistance; Female; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Recurrence; Young Adult | 2012 |
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Chronic Disease; Double-Blind Method; Elective Surgical Procedures; Female; Hemorrhage; Humans; Hydrazines; Liver Cirrhosis; Male; Middle Aged; Platelet Count; Platelet Transfusion; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; Young Adult | 2012 |
Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Bone Marrow Diseases; Chronic Disease; Female; Hematologic Neoplasms; Hemorrhage; Humans; Hydrazines; Liver Diseases; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome; Young Adult | 2013 |
Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP).
Topics: Adult; Aged; Benzoates; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Hematinics; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Treatment Outcome; Young Adult | 2013 |
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Receptors, Thrombopoietin; Recurrence; Thrombopoietin | 2007 |
Catecholaminergic drugs in chronic schizophrenia.
Topics: Adult; Apomorphine; Carbidopa; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Follicle Stimulating Hormone; Growth Hormone; Humans; Hydrazines; Imipramine; Levodopa; Luteinizing Hormone; Male; Middle Aged; Placebos; Schizophrenia, Disorganized; Testosterone | 1979 |
42 other study(ies) available for hydrazine and Chronic Disease
| Article | Year |
|---|---|
Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE.
Topics: Adult; Asia; Chronic Disease; Humans; Hydrazines; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Quality of Life; Turkey | 2023 |
Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
Topics: Adult; Canada; Chronic Disease; Hemorrhage; Humans; Hydrazines; Intracranial Hemorrhages; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Thrombocytopenia; Thrombopoietin | 2022 |
Efficacy and safety of eltrombopag in the treatment of Chinese children with chronic immune thrombocytopenia.
Topics: Benzoates; Child; Child, Preschool; China; Chronic Disease; Female; Humans; Hydrazines; Infant; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Retrospective Studies; T-Lymphocytes, Regulatory; Treatment Outcome | 2021 |
U.S. Food and Drug Administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Chronic Disease; Drug Approval; Female; Humans; Hydrazines; Infant; Male; Pyrazoles; Thrombocythemia, Essential; United States; United States Food and Drug Administration | 2017 |
Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Child; Child, Preschool; Chronic Disease; Female; Gene Expression Regulation; Humans; Hydrazines; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Splenectomy; Thrombopoietin; Time-to-Treatment; Treatment Outcome | 2018 |
A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists.
Topics: Benzoates; Chronic Disease; Clinical Decision-Making; Cost-Benefit Analysis; Costs and Cost Analysis; Decision Support Techniques; Drug Costs; Hemorrhage; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; United States | 2018 |
Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Chronic Disease; Female; Follow-Up Studies; Humans; Hydrazines; Male; Platelet Count; Prognosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Severity of Illness Index; Tertiary Care Centers; Thrombopoietin | 2019 |
A pH-sensitive near-infrared fluorescent probe with alkaline pK
Topics: Animals; Carbocyanines; Cell Line, Tumor; Chronic Disease; Diabetes Mellitus, Experimental; Fluorescent Dyes; Humans; Hydrazines; Hydrogen-Ion Concentration; Infrared Rays; Mice, Transgenic; Optical Imaging; Wounds and Injuries | 2019 |
Thrombopoietin receptor agonists as second-line therapy in splenectomy-eligible persistent immune thrombocytopenia: a case series.
Topics: Adrenal Cortex Hormones; Benzoates; Chronic Disease; Drug Resistance; Female; Humans; Hydrazines; Immunoglobulins, Intravenous; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Splenectomy; Thrombopoietin | 2019 |
Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopag.
Topics: Adult; Aged; Benzoates; Blood Loss, Surgical; Blood Platelets; Chronic Disease; Clinical Trials, Phase II as Topic; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Postoperative Hemorrhage; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Surgical Procedures, Operative; Thrombocytopenia | 2014 |
No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.
Topics: Benzoates; Chronic Disease; Drug Resistance; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Salvage Therapy; Thrombopoietin; Treatment Outcome | 2013 |
Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.
Topics: Adult; Autoantibodies; Benzoates; Blood Platelets; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2013 |
Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.
Topics: Antibodies, Monoclonal, Murine-Derived; Benzoates; Chronic Disease; Cost Savings; Cost-Benefit Analysis; Drug Costs; Female; Hemorrhage; Humans; Hydrazines; Immunoglobulins, Intravenous; Ireland; Male; Middle Aged; Platelet Count; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rituximab; Thrombocytopenia; Thrombopoietin | 2013 |
Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Benzoates; Blood Platelets; Chronic Disease; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computer Simulation; Female; Healthy Volunteers; Humans; Hydrazines; Liver Diseases; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Platelet Count; Pyrazoles; Randomized Controlled Trials as Topic; Thrombocytopenia; Treatment Outcome; Young Adult | 2014 |
Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
Topics: Benzoates; Chronic Disease; Dentistry, Operative; Hemorrhage; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome | 2015 |
Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children.
Topics: Adolescent; Benzoates; Child; Child, Preschool; Chronic Disease; Female; Humans; Hydrazines; Male; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Recombinant Fusion Proteins; Retrospective Studies; Thrombopoietin; Young Adult | 2014 |
Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Benzoates; Blood Platelets; Case-Control Studies; Chronic Disease; Gene Expression Regulation; Humans; Hydrazines; Megakaryocytes; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Signal Transduction; Thrombopoietin | 2014 |
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
Topics: Adult; Aged; Benzoates; Blood Platelets; Chronic Disease; Drug Administration Schedule; Drug Monitoring; Erythropoiesis; Female; Follow-Up Studies; Hematinics; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Recurrence; Remission Induction; Retrospective Studies; Splenectomy; Treatment Outcome | 2015 |
Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
Topics: Benzoates; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2015 |
Eltrombopag enhances platelet adhesion by upregulating the expression of glycoprotein VI in patients with chronic immune thrombocytopenic purpura.
Topics: Adult; Aged; Benzoates; Blood Platelets; Cell Adhesion; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Membrane Glycoproteins; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Up-Regulation; Young Adult | 2015 |
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
Topics: Aged; Benzoates; Chronic Disease; Female; Humans; Hydrazines; Immunosuppressive Agents; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Retreatment; Retrospective Studies; Spain; Treatment Outcome | 2016 |
Analgesic and Anti-Inflammatory Effects of the Novel Semicarbazide-Sensitive Amine-Oxidase Inhibitor SzV-1287 in Chronic Arthritis Models of the Mouse.
Topics: Amine Oxidase (Copper-Containing); Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents; Arthritis; Cells, Cultured; Chronic Disease; Disease Models, Animal; Disease Progression; Freund's Adjuvant; Humans; Hydrazines; Joints; Mice; Mice, Inbred Strains; Mice, Transgenic; Oxazoles; Oximes | 2017 |
New options after first-line therapy for chronic immune thrombocytopenic purpura.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzoates; Carrier Proteins; Chronic Disease; Drug Resistance; Humans; Hydrazines; Immunologic Factors; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Rituximab; Thrombopoiesis; Thrombopoietin | 2009 |
New therapy options for chronic immune thrombocytopenic purpura: a breath of fresh air. Introduction.
Topics: Benzoates; Chronic Disease; Drug Delivery Systems; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2009 |
Eltrombopag in chronic idiopathic thrombocytopenic purpura.
Topics: Benzoates; Chronic Disease; Double-Blind Method; Hemorrhage; Humans; Hydrazines; Multicenter Studies as Topic; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic | 2009 |
Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
Topics: Benzoates; Chronic Disease; Drug Approval; Humans; Hydrazines; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Sustaining platelet counts in chronic ITP.
Topics: Benzoates; Chronic Disease; Humans; Hydrazines; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin | 2011 |
Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chronic Disease; Female; Humans; Hydrazines; Male; Middle Aged; Platelet Activation; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome | 2011 |
Eltrombopag for chronic immune thrombocytopenia.
Topics: Asia; Benzoates; Chronic Disease; Humans; Hydrazines; Multicenter Studies as Topic; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin | 2011 |
Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura.
Topics: Benzoates; Chronic Disease; Humans; Hydrazines; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Remission Induction; Treatment Outcome | 2012 |
Usage of eltrombopag for chronic immune thrombocytopenia as a pretreatment for splenectomy.
Topics: Adult; Benzoates; Chronic Disease; Dexamethasone; Female; Glucocorticoids; Humans; Hydrazines; Prednisolone; Pyrazoles; Receptors, Thrombopoietin; Splenectomy; Thrombocytopenia | 2013 |
Chronic hypercortisolemia inhibits dopamine synthesis and turnover in the nucleus accumbens: an in vivo microdialysis study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Chronic Disease; Dopamine; Enzyme Inhibitors; Homovanillic Acid; Hydrazines; Hypercholesterolemia; Male; Microdialysis; Nucleus Accumbens; Prefrontal Cortex; Rats; Rats, Sprague-Dawley | 2002 |
Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT1 receptor blockade.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Captopril; Chronic Disease; Coronary Vessels; Disease Models, Animal; Endothelium-Dependent Relaxing Factors; Endothelium, Vascular; Fatty Acids, Unsaturated; Heart; Heart Failure; Hydrazines; Imidazoles; Indomethacin; Lisinopril; Losartan; Male; Mesenteric Arteries; Nitric Oxide; omega-N-Methylarginine; Pyridines; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Superoxide Dismutase; Sympathetic Nervous System; Tetrazoles; Tetrodotoxin; Vascular Resistance | 2003 |
Acceleration therapy of recurrent depressions.
Topics: Acceleration; Chronic Disease; Depression; Depressive Disorder; Depressive Disorder, Major; Hydrazines | 1961 |
Effects of acute, repeated and chronic variable stress on in vivo tyrosine hydroxylase activity and on alpha(2)-adrenoceptor sensitivity in the rat brain.
Topics: Acute Disease; Adrenergic alpha-Agonists; Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Brain; Chronic Disease; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hippocampus; Hydrazines; Hypothalamus; Male; Norepinephrine; Oxymetazoline; Pain; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Recurrence; Stress, Physiological; Tail; Time Factors; Tyrosine 3-Monooxygenase | 2003 |
Ambulatory long-term vasodilator therapy for chronic refractory heart failure: hemodynamic evaluation and clinical response.
Topics: Adult; Aged; Ambulatory Care; Cardiac Catheterization; Cardiomyopathy, Dilated; Chronic Disease; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Hydrazines; Isosorbide Dinitrate; Long-Term Care; Male; Middle Aged; Mitral Valve Insufficiency; Stroke Volume; Todralazine | 1984 |
[Clinical and psychological criteria of early detection of hazardous effects of components of synthetic hydrocarbon fuel].
Topics: Adult; Air Pollutants, Occupational; Chronic Disease; Ethylene Glycols; Female; Fuel Oils; Humans; Hydrazines; Hydrocarbons; Male; Mental Disorders; Middle Aged; Occupational Diseases; Occupations; Space Flight | 1997 |
Enhanced tyrosine hydroxylation in hippocampus of chronically stressed rats upon exposure to a novel stressor.
Topics: alpha-Methyltyrosine; Animals; Chronic Disease; Dihydroxyphenylalanine; Extracellular Space; Hippocampus; Hydrazines; Hydroxylation; Male; Methyltyrosines; Rats; Rats, Inbred Strains; Stress, Physiological; Tyrosine; Tyrosine 3-Monooxygenase | 1992 |
Role of prostaglandin H2-thromboxane A2 in responses of cerebral arterioles during chronic hypertension.
Topics: Acetylcholine; Adenosine Diphosphate; Animals; Arterioles; Brain; Bridged Bicyclo Compounds, Heterocyclic; Chronic Disease; Fatty Acids, Unsaturated; Hydrazines; Hypertension; Imidazoles; Male; Nitroglycerin; Prostaglandin Endoperoxides, Synthetic; Prostaglandin H2; Prostaglandins H; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Thromboxane A2; Vasodilator Agents | 1992 |
[Morphological and biochemical effects of chronic intoxication with hydrazine hydrate in guinea pigs].
Topics: Animals; Carbohydrate Metabolism; Chronic Disease; Fatty Liver; Guinea Pigs; Hydrazines; Kidney Diseases; Lipid Metabolism; Liver; Male | 1973 |
[Treatment of chronic bronchial asthma with methylhydrazine (25 cases)].
Topics: Antigen-Antibody Reactions; Asthma; Bronchopneumonia; Chronic Disease; Drug Tolerance; Humans; Hydrazines; Immunosuppressive Agents | 1969 |
[1st experience in the treatment of chronic hepatitis with 6-mercaptopurine and a methylhydrazine derivative].
Topics: Biopsy; Blood Chemical Analysis; Chronic Disease; Hepatitis; Humans; Hydrazines; Injections, Intravenous; Mercaptopurine | 1965 |